Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2013

01-05-2013 | Letter to the Editor

Splenectomy followed by administration of rituximab is useful to treat a patient with hairy cell leukemia-variant

Authors: Tetsumi Yoshida, Keichiro Mihara, Sayaka Sugihara, Koji Arihiro, Tatsuji Mino, Naomi Sasaki, Yoshihiro Takihara

Published in: Annals of Hematology | Issue 5/2013

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon
2.
Hockley SL, Else M, Morilla A et al (2012) The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol 158:347–354PubMedCrossRef
3.
Robak T (2011) Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 37:3–10PubMedCrossRef
4.
Jones G, Parry-Jones N, Wilkins B et al (2011) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol 156:186–195PubMedCrossRef
5.
Narat S, Gandla J, Dogan A, Mehta A (2005) Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 46:1229–1232PubMedCrossRef
6.
Quach H, Januszewicz H, Westerman D (2005) Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica 90:e72–e73
7.
Metadata
Title
Splenectomy followed by administration of rituximab is useful to treat a patient with hairy cell leukemia-variant
Authors
Tetsumi Yoshida
Keichiro Mihara
Sayaka Sugihara
Koji Arihiro
Tatsuji Mino
Naomi Sasaki
Yoshihiro Takihara
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 5/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1612-1

Other articles of this Issue 5/2013

Annals of Hematology 5/2013 Go to the issue

Original Article

Association of vitamin D deficiency and anemia in a hospitalized geriatric population: denutrition as a confounding factor

Original Article

Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia

Original Article

Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia

Erratum

Erratum to: High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

Original Article

Cytological characterization of murine bone marrow and spleen hematopoietic compartments for improved assessment of toxicity in preclinical gene marking models

Original Article

Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits